scholarly article | Q13442814 |
P356 | DOI | 10.1038/NM.2221 |
P953 | full work available at URL | http://www.nature.com/articles/nm.2221.pdf |
http://www.nature.com/articles/nm.2221 | ||
P698 | PubMed publication ID | 21052077 |
P2093 | author name string | Kaj Blennow | |
P2860 | cites work | Lewy Body Pathology in Alzheimer's Disease | Q22241400 |
The clinical use of structural MRI in Alzheimer disease | Q24609648 | ||
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo | Q24679444 | ||
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics | Q27860914 | ||
A beta oligomers - a decade of discovery | Q29615152 | ||
Alzheimer's disease | Q29616743 | ||
Effects of gamma-secretase inhibition on the amyloid beta isoform pattern in a mouse model of Alzheimer's disease | Q30940227 | ||
Donepezil effects on cerebral blood flow in older adults with mild cognitive deficits | Q31041952 | ||
Alzheimer's disease: clinical trials and drug development | Q33349401 | ||
The neuropathology of probable Alzheimer disease and mild cognitive impairment | Q33616561 | ||
A novel Abeta isoform pattern in CSF reflects gamma-secretase inhibition in Alzheimer disease | Q33877903 | ||
Thinking outside the box: Alzheimer-type neuropathology that does not map directly onto current consensus recommendations | Q33943520 | ||
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial | Q33988701 | ||
Acute gamma-secretase inhibition of nonhuman primate CNS shifts amyloid precursor protein (APP) metabolism from amyloid-beta production to alternative APP fragments without amyloid-beta rebound | Q34036136 | ||
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease | Q34098866 | ||
Vitamin E and donepezil for the treatment of mild cognitive impairment | Q34411313 | ||
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. | Q34417339 | ||
Safety, tolerability, pharmacokinetics, and Abeta levels after short-term administration of R-flurbiprofen in healthy elderly individuals | Q34727482 | ||
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial | Q34798154 | ||
Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment | Q35172333 | ||
Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease | Q37192883 | ||
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects | Q37227424 | ||
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system | Q37316153 | ||
The use of PET in Alzheimer disease | Q37688880 | ||
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study | Q37699953 | ||
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives | Q37769104 | ||
Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial | Q40064054 | ||
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study | Q40349700 | ||
Existing plaques and neuritic abnormalities in APP:PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575. | Q41989700 | ||
Acute effect on the Aβ isoform pattern in CSF in response to γ-secretase modulator and inhibitor treatment in dogs | Q42968955 | ||
Pittsburgh compound-B and Alzheimer's disease biomarkers in CSF, plasma and urine: An exploratory study | Q43120526 | ||
Donepezil HCl (E2020) maintains functional brain activity in patients with Alzheimer disease: results of a 24-week, double-blind, placebo-controlled study | Q44336275 | ||
Randomized, Placebo-Controlled Trial of the Effects of Donepezil on Neuronal Markers and Hippocampal Volumes in Alzheimer’s Disease | Q44640384 | ||
CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. | Q45923691 | ||
Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? | Q46412583 | ||
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial | Q46616657 | ||
Neurochemical dissection of synaptic pathology in Alzheimer's disease. | Q47965884 | ||
Identification of synaptic vesicle, pre- and postsynaptic proteins in human cerebrospinal fluid using liquid-phase isoelectric focusing | Q48227034 | ||
Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. | Q48893777 | ||
Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. | Q51867713 | ||
Intra-individual stability of CSF biomarkers for Alzheimer's disease over two years. | Q51969054 | ||
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. | Q51986028 | ||
Longitudinal stability of CSF biomarkers in Alzheimer's disease. | Q53286684 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Alzheimer's disease | Q11081 |
biomarker | Q864574 | ||
P304 | page(s) | 1218-1222 | |
P577 | publication date | 2010-09-21 | |
P1433 | published in | Nature Medicine | Q1633234 |
P1476 | title | Biomarkers in Alzheimer's disease drug development | |
P478 | volume | 16 |
Q57285591 | A neuropathologic diagnosis of Alzheimer's disease in an older adult with HIV-associated neurocognitive disorder |
Q42655623 | Accelerating drug development for Alzheimer's disease through the use of data standards |
Q89703430 | Alleviation of symptoms of Alzheimer's disease by diminishing Aβ neurotoxicity and neuroinflammation |
Q34746609 | An enzyme-generated fragment of tau measured in serum shows an inverse correlation to cognitive function |
Q91963536 | Application of Electrochemical Aptasensors toward Clinical Diagnostics, Food, and Environmental Monitoring: Review |
Q30651551 | Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease |
Q27021625 | Blood markers of oxidative stress in Alzheimer's disease |
Q59049398 | CSF Biomarkers of Alzheimer’s Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design |
Q37485864 | CSF Presenilin-1 complexes are increased in Alzheimer's disease |
Q35846251 | Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort |
Q38825497 | Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice |
Q34746995 | Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia |
Q37022572 | Clinical correlates of longitudinal brain atrophy in progressive supranuclear palsy |
Q39820325 | Clinical trials of disease-modifying therapies for neurodegenerative diseases: the challenges and the future |
Q38778638 | Defeating Alzheimer's disease and other dementias: a priority for European science and society |
Q35394390 | Dementia and Alzheimer's disease: a new direction.The 2010 Jay L. Foster Memorial Lecture |
Q37960496 | Detection of Soluble Amyloid-β Oligomers and Insoluble High-Molecular-Weight Particles in CSF: Development of Methods with Potential for Diagnosis and Therapy Monitoring of Alzheimer's Disease |
Q55427595 | Development and Optimization of a Fluorescent Imaging System to Detect Amyloid-β Proteins: Phantom Study. |
Q35910923 | Endpoints for Pre-Dementia AD Trials: A Report from the EU/US/CTAD Task Force |
Q36071403 | Evidence for ordering of Alzheimer disease biomarkers |
Q33862796 | Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects |
Q24289435 | Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research |
Q92624766 | HENA, heterogeneous network-based data set for Alzheimer's disease |
Q37190009 | Improved design of prodromal Alzheimer's disease trials through cohort enrichment and surrogate endpoints |
Q47141112 | Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics |
Q51894031 | Learning from genetic forms of neurodegeneration. |
Q33687554 | Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease |
Q37585625 | Magnetic resonance imaging for monitoring therapeutic response in a transgenic mouse model of Alzheimer's disease using voxel-based analysis of amyloid plaques |
Q38666481 | Modeling Alzheimer's disease with human induced pluripotent stem (iPS) cells |
Q30881333 | Molecular imaging biomarkers for dementia with Lewy bodies: an update |
Q42111862 | Molecular interactions of Alzheimer's biomarker FDDNP with Aβ peptide |
Q82769587 | Neurodegeneration and the neuroimmune system |
Q82769596 | Neurodegeneration and the neurovascular unit |
Q38127470 | Novel disease-modifying therapeutics for the treatment of Alzheimer's disease. |
Q38101555 | Perspectives on episodic-like and episodic memory |
Q27001550 | Platelets and Alzheimer's disease: Potential of APP as a biomarker |
Q36055870 | Posterior Cingulate Lactate as a Metabolic Biomarker in Amnestic Mild Cognitive Impairment. |
Q38053449 | Potential sources of interference on Abeta immunoassays in biological samples |
Q38704916 | Rethinking on the concept of biomarkers in preclinical Alzheimer's disease |
Q94521330 | SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease |
Q57971994 | Searching for biomarkers in neurodegeneration |
Q36677361 | Shapes of the trajectories of 5 major biomarkers of Alzheimer disease |
Q49121401 | Specific self-monitoring of metal-associated amyloid-β peptide disaggregation by a fluorescent chelator |
Q30396334 | The Assessment of the Readiness of Molecular Biomarker-Based Mobile Health Technologies for Healthcare Applications |
Q52644601 | The Past and the Future of Alzheimer's Disease Fluid Biomarkers. |
Q82318245 | The benefits and limitations of animal models for translational research in neurodegenerative diseases |
Q38907580 | The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system |
Q34026317 | The future of blood-based biomarkers for Alzheimer's disease |
Q26781635 | The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events |
Q26853347 | The potential of pathological protein fragmentation in blood-based biomarker development for dementia - with emphasis on Alzheimer's disease |
Q38530095 | Transmembrane Amyloid-Related Proteins in CSF as Potential Biomarkers for Alzheimer's Disease |
Q59800332 | Uncovering Biologically Coherent Peripheral Signatures of Health and Risk for Alzheimer’s Disease in the Aging Brain |
Q53446502 | Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. |
Q83088740 | Use of biomarkers in clinical trials of Alzheimer disease: from concept to application |
Q53396427 | White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. |